128 related articles for article (PubMed ID: 38831733)
1. Choice of antiretroviral therapy has low impact on weight gain.
Drechsler H; Ayers C; Oboho I; Enwerem N; Hanna J; Clark C; Kitchell E; Jain M; Luque A; Bedimo R
AIDS; 2024 Jun; ():. PubMed ID: 38831733
[TBL] [Abstract][Full Text] [Related]
2. Real-World Analysis of Weight Gain and Body Mass Index Increase Among Patients with HIV-1 Using Antiretroviral Regimen Containing Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, or Neither in the United States.
Emond B; Rossi C; Rogers R; Lefebvre P; Lafeuille MH; Donga P
J Health Econ Outcomes Res; 2022; 9(1):39-49. PubMed ID: 35233432
[No Abstract] [Full Text] [Related]
3. Recent data on the role of antiretroviral therapy in weight gain and obesity in persons living with HIV.
Capeau J; Lagathu C; Béréziat V
Curr Opin HIV AIDS; 2024 Jan; 19(1):14-20. PubMed ID: 38078606
[TBL] [Abstract][Full Text] [Related]
4. Weight and body mass index increase after switch from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate-containing treatment in an antiretroviral therapy-experienced group.
Łomiak M; Stępnicki J; Mikuła T; Wiercińska-Drapało A
Int J STD AIDS; 2021 May; 32(6):570-577. PubMed ID: 33612018
[TBL] [Abstract][Full Text] [Related]
5. Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts.
Byonanebye DM; Polizzotto MN; Maltez F; Rauch A; Grabmeier-Pfistershammer K; Wit F; De Wit S; Castagna A; d'Arminio Monforte A; Mussini C; Wasmuth JC; Fontas E; Abela I; Sarcletti M; Bansi-Matharu L; Jaschinski N; Peters L; Hosein SR; Vannappagari V; Cohen C; Bissio E; Mocroft A; Law M; Ryom L; Petoumenos K;
Lancet HIV; 2024 May; 11(5):e321-e332. PubMed ID: 38621392
[TBL] [Abstract][Full Text] [Related]
6. Antiretroviral Therapy Anchor-based Trends in Body Mass Index Following Treatment Initiation Among Military Personnel with HIV.
Kline MDA; Daniels C; Xu X; Sunil T; Ganesan A; Agan BK; Colombo RE; Kronmann KC; Blaylock JM; Okulicz JF; Markelz AE
Mil Med; 2021 Feb; 186(3-4):279-285. PubMed ID: 33128552
[TBL] [Abstract][Full Text] [Related]
7. Weight gain before and after switch from TDF to TAF in a U.S. cohort study.
Mallon PW; Brunet L; Hsu RK; Fusco JS; Mounzer KC; Prajapati G; Beyer AP; Wohlfeiler MB; Fusco GP
J Int AIDS Soc; 2021 Apr; 24(4):e25702. PubMed ID: 33838004
[TBL] [Abstract][Full Text] [Related]
8. Brief Report: Weight Gain Following ART Initiation in ART-Naïve People Living With HIV in the Current Treatment Era.
Ruderman SA; Crane HM; Nance RM; Whitney BM; Harding BN; Mayer KH; Moore RD; Eron JJ; Geng E; Mathews WC; Rodriguez B; Willig AL; Burkholder GA; Lindström S; Wood BR; Collier AC; Vannappagari V; Henegar C; Van Wyk J; Curtis L; Saag MS; Kitahata MM; Delaney JAC
J Acquir Immune Defic Syndr; 2021 Mar; 86(3):339-343. PubMed ID: 33148997
[TBL] [Abstract][Full Text] [Related]
9. Weight changes after antiretroviral therapy initiation in CoRIS (Spain): a prospective multicentre cohort study.
Martínez-Sanz J; Blanco JR; Muriel A; Pérez-Elías MJ; Rubio-Martín R; Berenguer J; Peraire J; Bernal E; Martínez OJ; Serrano-Villar S; Moreno S;
J Int AIDS Soc; 2021 May; 24(5):e25732. PubMed ID: 34036745
[TBL] [Abstract][Full Text] [Related]
10. Comparison of weight gain after antiretroviral switch to integrase strand transfer inhibitor or tenofovir alafenamide-based therapy.
Sjaarda A; Bernstein A; Sparks A; Saber S; Siegel M
Infection; 2022 Apr; 50(2):407-412. PubMed ID: 34449049
[TBL] [Abstract][Full Text] [Related]
11. Adipocyte differentiation of 3T3-L1 cells under tenofovir alafenamide, tenofovir disoproxil fumarate, and integrase strand transfer inhibitors selective challenge: an in-vitro model.
Perna A; Carleo MA; Mascolo S; Guida A; Contieri M; Sellitto C; Hay E; De Blasiis P; Lucariello A; Guerra G; Baldi A; De Luca A; Maggi P; Esposito V
AIDS; 2023 Mar; 37(4):561-570. PubMed ID: 36504092
[TBL] [Abstract][Full Text] [Related]
12. Weight and Body Mass Index Change After Switching to Integrase Inhibitors or Tenofovir Alafenamide Among Women Living with HIV.
Lahiri CD; Xu Y; Wang K; Alvarez JA; Sheth AN; O'Halloran J; Spence AB; Tien P; Gustafson DR; Milam J; Fischl MA; Konkle-Parker D; Adimora AA; Sharma A; Weber KM; Ofotokun I; Rubin LH
AIDS Res Hum Retroviruses; 2021 Jun; 37(6):461-467. PubMed ID: 33231474
[TBL] [Abstract][Full Text] [Related]
13. Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical Trials.
Erlandson KM; Carter CC; Melbourne K; Brown TT; Cohen C; Das M; Esser S; Huang H; Koethe JR; Martin H; McComsey GA; Orkin C; Post FA; Rockstroh JK; Sax PE; Stellbrink HJ; Waters L; Wei X; Lake JE
Clin Infect Dis; 2021 Oct; 73(8):1440-1451. PubMed ID: 33987636
[TBL] [Abstract][Full Text] [Related]
14. Weight Change When Initiating, Switching to, and Discontinuing Integrase Strand Transfer Inhibitors in People Living with HIV.
Tieosapjaroen W; Chow EPF; Fairley CK; Hoy J; Aguirre I; Ong JJ
AIDS Patient Care STDS; 2023 Mar; 37(3):131-137. PubMed ID: 36809049
[TBL] [Abstract][Full Text] [Related]
15. Weight Change and Predictors of Weight Change Among Patients Initiated on Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Real-World Retrospective Study.
Emond B; Rossi C; Côté-Sergent A; Dunn K; Lefebvre P; Lafeuille MH; Donga P
J Health Econ Outcomes Res; 2021 Jun; 8(1):88-98. PubMed ID: 34179212
[No Abstract] [Full Text] [Related]
16. Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor-Based Regimens.
Norwood J; Turner M; Bofill C; Rebeiro P; Shepherd B; Bebawy S; Hulgan T; Raffanti S; Haas DW; Sterling TR; Koethe JR
J Acquir Immune Defic Syndr; 2017 Dec; 76(5):527-531. PubMed ID: 28825943
[TBL] [Abstract][Full Text] [Related]
17. Comparative study of antiretroviral drug regimens and drug-drug interactions between younger and older HIV-infected patients at a tertiary care teaching hospital in South Korea.
Park MS; Yang YM; Kim JS; Choi EJ
Ther Clin Risk Manag; 2018; 14():2229-2241. PubMed ID: 30519031
[TBL] [Abstract][Full Text] [Related]
18. A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015-2017.
Gomez M; Seybold U; Roider J; Härter G; Bogner JR
Infection; 2019 Feb; 47(1):95-102. PubMed ID: 30269210
[TBL] [Abstract][Full Text] [Related]
19. Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials.
Sax PE; Erlandson KM; Lake JE; Mccomsey GA; Orkin C; Esser S; Brown TT; Rockstroh JK; Wei X; Carter CC; Zhong L; Brainard DM; Melbourne K; Das M; Stellbrink HJ; Post FA; Waters L; Koethe JR
Clin Infect Dis; 2020 Sep; 71(6):1379-1389. PubMed ID: 31606734
[TBL] [Abstract][Full Text] [Related]
20. Weight, anthropometric and metabolic changes after discontinuing antiretroviral therapy containing tenofovir alafenamide (TAF) in people with HIV.
Damas J; Munting A; Fellay J; Haerry D; Marzolini C; Tarr PE; Steffen A; Braun DL; Stoeckle M; Bernasconi E; Tshikung ON; Fux CA; Darling KEA; Béguelin C; Wandeler G; Cavassini M; Surial B;
Clin Infect Dis; 2024 Apr; ():. PubMed ID: 38606792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
